Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesA Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors
Clinical Cancer Research, 08/18/06
Elizabeth Fox, et al. - Conclusion: ABT-751 is well tolerated in children. The recommended dose for phase 2 trials in solid tumors is 200 mg/m2/d administered orally, daily for 7 days every 21 days. This dose is >40% higher than the maximum tolerated dose in adults receiving the same dosing schedule
Related Articles
Delays in Diagnosis of Pediatric Solid Tumors in Singapore
Journal of Pediatric Hematology/Oncology, 11/11/09
Relevance Score: 93%%
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial
Journal of Clinical Oncology, 11/30/09
Relevance Score: 91%%
A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors
Cancer Chemotherapy and Pharmacology, 12/03/09
Relevance Score: 89%%
Musculoskeletal manifestations in patients with malignant disease
Clinical Rheumatology, 11/16/09
Relevance Score: 89%%
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas
Cancer Chemotherapy and Pharmacology, 11/12/09
Relevance Score: 89%%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
New agents for AML and MDS
Best Practice & Research: Clinical Haematology , 12/08/09
New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents
Biologics: targets & therapy, 12/08/09
Review: erythropoiesis-stimulating agents increase mortality in patients with cancer
Evidence-Based Medicine, 12/08/09
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Autologous blood therapy for common cold—A randomized, double-blind, placebo-controlled trial
Complementary Therapies in Medicine, 12/08/09
Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial
Archives of Drug Information, 12/08/09
Reduction of biofilm formation with trisodium citrate in haemodialysis catheters: a randomized controlled trial
Nephrology Dialysis Transplantation, 12/08/09
Sponsor
Article Search
Sponsor